MedTrace Logo

Survival Benefit of Compound Kushen Injection in the Treatment of Advanced Colorectal Cancer

NCT05894694 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 320

Last updated 2024-12-27

No results posted yet for this study

Summary

To clarify the effectiveness and safety of compound kushen injection in the treatment of advanced colorectal cancer.

Conditions

  • Advanced Colorectal Carcinoma

Interventions

DRUG

first-line scheme+compound kushen injection

FOLFOX/FOLFIRI/CAPEOX± Cetuximab/bevacizumab+compound kushen injection Compound Kushen injection: intravenous infusion, 20ml at a time, diluted with 200ml sodium chloride injection, once a day, each cycle of chemotherapy should reach the cumulative dose of 200ml.

DRUG

palliative care group first-line scheme

FOLFOX/FOLFIRI/CAPEOX± Cetuximab/bevacizumab

Sponsors & Collaborators

  • Guang'anmen Hospital of China Academy of Chinese Medical Sciences

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-27
Primary Completion
2025-12-30
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05894694 on ClinicalTrials.gov